Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP lifted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 137.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 140,690 shares of the company’s stock after acquiring an additional 81,354 shares during the period. Wellington Management Group LLP owned approximately 0.23% of Immunome worth $2,057,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of IMNM. Point72 Asset Management L.P. grew its position in Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after purchasing an additional 85,580 shares during the last quarter. Janus Henderson Group PLC lifted its position in Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after acquiring an additional 324,614 shares during the period. MetLife Investment Management LLC grew its stake in Immunome by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 30,265 shares of the company’s stock valued at $442,000 after purchasing an additional 17,053 shares during the last quarter. FMR LLC increased its holdings in shares of Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after purchasing an additional 13,757 shares during the period. Finally, Cerity Partners LLC raised its stake in shares of Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after purchasing an additional 5,043 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IMNM. Piper Sandler cut their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Finally, Stephens assumed coverage on Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $28.83.

Insider Activity

In related news, CEO Clay B. Siegall purchased 66,057 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average price of $9.54 per share, with a total value of $630,183.78. Following the purchase, the chief executive officer now owns 485,693 shares of the company’s stock, valued at $4,633,511.22. The trade was a 15.74 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CTO Philip Tsai purchased 21,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average cost of $9.43 per share, with a total value of $198,030.00. Following the acquisition, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired 102,862 shares of company stock worth $978,045 over the last three months. 8.60% of the stock is currently owned by corporate insiders.

Immunome Trading Down 7.6 %

NASDAQ IMNM opened at $11.11 on Thursday. The stock has a market capitalization of $693.45 million, a price-to-earnings ratio of -1.37 and a beta of 1.83. The stock has a 50-day moving average of $12.18 and a 200 day moving average of $13.39. Immunome, Inc. has a twelve month low of $7.76 and a twelve month high of $30.96.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.